Company: PSTV
Filing Date: 2025-06-17
Form Type: 8-K
Source: 0001193125-25-142093
Chunk: 0

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-17
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry into a Material Definitive Agreement.  

As previously disclosed, on March 4, 2025, Plus Therapeutics, Inc. (the “ Company”) entered into that certain Securities Purchase Agreement, dated March 4, 2025 (the “ Purchase Agreement”), with the various purchasers party thereto (the “ Purchasers”), pursuant to which the Company issued to such Purchasers in an private placement (the “ March 2025 Private Placement”) the following securities of the Company: (i) an aggregate of 4,069,738 shares (the “ Private Placement Shares”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock”), (ii) prefunded warrants (the“ Pre-FundedWarrants”) to purchase an aggregate of up to 23,972,400 shares of Common Stock (the “ Prefunded Warrant Shares”), (iii) Series A Warrants (the “ Series A Warrants”) to purchase up to an aggregate of 280,421,380 shares of Common Stock (assuming full adjustment based on the floor price specified in the Series A Warrants) (the “ Series A Warrant Shares”), and (iv) Series B Warrants (the “ Series B Warrants”) to purchase up to an aggregate of 1,261,896,210 shares of Common Stock (assuming full adjustment based on the floor price specified in the Series B Warrants and accounting for the alternative cashless exercise feature of 3:1 contained therein) (the “ Series B Warrant Shares”).

On June 17, 2025, the Company and the Purchasers entered into a letter agreement (the “ Letter Agreement”) with each of the Purchasers in an effort to, among other items, minimize the dilutive impact of the March 2025 Private Placement. Pursuant to the Letter Agreement:

  Cancellation of Series A Warrants. The Company and each of the Purchasers agreed to terminate all Series A Warrants in full.  

  Amendment of Series B Warrants. The Company and each of the Purchasers agreed to amend all outstanding Series B Warrants in the form of Exhibit 4.1 hereto (the “ Amended Series B Warrants”) to ...  

  Waiver of Registration Rights Agreement. The Company and each of the Purchasers agreed to terminate the Registration Rights Agreement and nullify all past, present and future obligations with r...  

  Return of Private Placement Shares and Pre-Funded W